BioCentury | Jul 10, 2020

Nkarta’s $252M IPO among biggest preclinical listings ever

Nkarta had already beaten expectations by pricing its upsized IPO at $18, but its triple-digit aftermarket gains provided further evidence that the powerful appetite for new biotech listings extends to preclinical companies. The company more...
BioCentury | Sep 4, 2019

Nkarta’s $114M series B to fund clinical NK cell programs, manufacturing facility

After stretching its $11.5 million series A round to bring its most advanced preclinical NK cell programs within a year of IND submissions while assembling a management team with expertise ranging from discovery to manufacturing,...
BioCentury | Sep 14, 2018

Zai shores up

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter,...
BioCentury | Jul 13, 2018
Company News

Pilot supports real-world endpoints as surrogates for OS

Friends of Cancer Research released data on July 10 that support the use of real-world evidence (RWE) outcomes -- including real-world progression-free survival (rwPFS) -- as surrogate endpoints for overall survival to evaluate a treatment's...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...expressed developmentally down-regulated 8 (NEDD8) 5 1 Nicotinamide phosphoribosyltransferase (NamPRT; NAMPT) 4 1 NK2 homeobox 1 (NKX2-1; TTF1...
BioCentury | May 16, 2017
Distillery Techniques


TECHNOLOGY: Gene profiling Tumor levels of eight proteins could help predict survival in melanoma. In patients, low tumor levels of eight tumor suppressors -- tumor necrosis factor α-induced protein 3 ( TNFAIP3 ; A20), PR domain...
BioCentury | Nov 3, 2014
Clinical News

HA-Irinotecan: Phase III data

The double-blind, Australian Phase III ACO002 trial in 415 irinotecan-naive patients who failed previous therapy showed that HA-Irinotecan as part of FOLFIRI therapy as second- or third-line treatment missed the primary endpoint of improving median...
BioCentury | Jun 23, 2014
Clinical News

HA-Irinotecan: Phase III ongoing

Alchemia said it now expects to report top-line data from the double-blind, international Phase III ACO002 trial of HA-Irinotecan before the end of 3Q14. The company, which previously said it expected data this half, said...
BioCentury | Dec 9, 2013
Clinical News

HA-Irinotecan: Phase III ongoing

Alchemia said an independent DSMB recommended for the fourth time continuation of the double-blind, international Phase III ACO002 trial of HA-Irinotecan after a review of all patients found no safety concerns. The trial is comparing...
BioCentury | May 16, 2013
Tools & Techniques

Myelination gets direct

Separate groups at the Case Western Reserve University School of Medicine and the Stanford University School of Medicine have developed similar approaches to directly reprogram rodent fibroblasts into oligodendrocyte progenitor cells. 1,2 The direct lineage...
Items per page:
1 - 10 of 43